<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988413</url>
  </required_header>
  <id_info>
    <org_study_id>SYHA1402201801/PRO-1</org_study_id>
    <nct_id>NCT03988413</nct_id>
  </id_info>
  <brief_title>Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People</brief_title>
  <official_title>Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Ascending Trial of SYHA1402 Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial used single-center, randomized, double-blind, placebo-controlled, single-dose
      study.

      The trial planned to enroll sixty-two healthy volunteers. The subjects were allocated to
      seven dose groups, including 25 mg (4+2), 50 mg (8+2), 100 mg (8+2), 200 mg (8+2), 400 mg
      (8+2), 800 mg (6+2) and 1200 mg (6+2). Each dose group was allocated test drugs and placebos
      according to the proportion of subjects in the brackets mentioned above.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Actual">January 14, 2020</completion_date>
  <primary_completion_date type="Actual">January 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of systolic blood pressure and diastolic blood pressure</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>To assess the change of blood pressure after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of heart rate</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>To assess the change of heart rate after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of pulse</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>To assess pulse after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of body temperature</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 hours</time_frame>
    <description>To assess the change of body temperature after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of 12-lead ECG</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8, 24, 48, 72 hours</time_frame>
    <description>To assess the change of 12-lead ECG (PR，QRS，QT，QTc) after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of physical examination</measure>
    <time_frame>24, 48, 72 hours</time_frame>
    <description>To assess the change of physical examination (including cardiovascular system, chest and lung, abdomen, nervous system, skeletal muscle system, etc) after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of blood biochemistry</measure>
    <time_frame>24, 48, 72 hours</time_frame>
    <description>To assess the change of blood biochemistry (including LDL, HDL,TC, ALT, AST, etc) after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chagne of blood routine</measure>
    <time_frame>24, 48, 72 hours</time_frame>
    <description>To assess the change of blood routine after administration of SYHA1402</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of urinary routine</measure>
    <time_frame>24, 48, 72 hours</time_frame>
    <description>To assess the change of urinary routine after administration of SYHA1402</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>10minutes, 20minutes, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>Plasma peak concentration (Cmax) after administration of SYHA1402</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak time (Tmax)</measure>
    <time_frame>10minutes, 20minutes, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>Plasma peak time (Tmax) after administration of SYHA1402</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-72h)</measure>
    <time_frame>10minutes, 20minutes, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>The area under the plasma concentration-time curve of SYHA1402 after administration are calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half time (t1/2)</measure>
    <time_frame>10minutes, 20minutes, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>The half time of SYHA1402 after administration are calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>10minutes, 20minutes, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>To assess the apparent clearance (CL/F) after administration of SYHA1402</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of SYHA1402</measure>
    <time_frame>10minutes, 20minutes, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>To assess the Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of SYHA1402</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Diabetic Neuropathy Peripheral</condition>
  <arm_group>
    <arm_group_label>25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, Oral, 25mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, Oral, 50mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, Oral, 100mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, Oral, 200mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, Oral, 400mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, Oral, 800mg, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25mg</intervention_name>
    <description>SYHA1402 25mg or Placebo 25mg</description>
    <arm_group_label>25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50mg</intervention_name>
    <description>SYHA1402 50mg or Placebo 50mg</description>
    <arm_group_label>50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mg</intervention_name>
    <description>SYHA1402 100mg or Placebo 100mg</description>
    <arm_group_label>100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200mg</intervention_name>
    <description>SYHA1402 200mg or Placebo 200mg</description>
    <arm_group_label>200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400mg</intervention_name>
    <description>SYHA1402 400mg or Placebo 400mg</description>
    <arm_group_label>400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800mg</intervention_name>
    <description>SYHA1402 800mg or Placebo 800mg</description>
    <arm_group_label>800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18≤Age≤45, male or female;

          2. Body weight (&gt; 45.0 kg (female) or 50.0 kg (male), 19.0 kg/m2 (&lt; BMI) = 26.0 kg/m2);

          3. Subjects with normal clinical significance by medical history, vital signs, physical
             examination and laboratory examination;

          4. All subjects who adopt effective non-hormonal contraceptive measures (such as condoms,
             intrauterine devices without drugs, etc.) from the signing of informed consent to
             three months after the end of the study;

          5. Subjects who voluntarily signed the informed consent and are able to cooperate to
             complete the test according to the protocal.

        Exclusion Criteria:

          1. Female subjects: pregnant or lactating, or planned pregnancy; male subjects: their
             partner planned pregnancy, or planned to donate sperm;

          2. Have neurological or psychiatric diseases history, or have serious cardiovascular,
             liver and kidney, endocrine, respiratory, blood, digestive, immune and other systemic
             diseases history;

          3. Surgery history within six months before signing the informed consent;

          4. Allergic history to more than one drug or other serious allergic rhistory.

          5. Subjects with a QTc interval greater than 450 ms (male) or 470 MS (female), or with a
             history of prolonged QTc interval;

          6. Positive with serum immunological test for HBsAg, Anti-HCV, Anti-HIV or Anti-TP;

          7. History of drugs or drug abuse or alcoholics;

          8. History of blood donation more than 200 mL within 8 weeks before signing informed
             consent;

          9. Subjects participating in other clinical trials, or who have participated in any other
             clinical trials of drugs within three months before signing informed consent;

         10. Not suitable for this trial according to the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The General Hospital of the People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

